Results 271 to 280 of about 440,184 (328)

Low prognostic nutritional index predicts poor outcome in newly diagnosed angioimmunoblastic T-cell lymphoma. [PDF]

Front Nutr
Li R, Zhang W, Yu L, Wu P, Huang H, Guo H, Lin T, Hong H, Weng H.   +8 more
europepmc   +1 more source

A case of angioimmunoblastic T-cell lymphoma mimicking angioedema. [PDF]

Discov Oncol
Zhao H, Xia Y, Su F, Chen L, Hu B.
europepmc   +1 more source

Real‐world clinical experience with NGS‐based chimerism analyses in haematopoietic stem cell transplant patients

British Journal of Haematology, EarlyView.
This study demonstrates the clinical utility of a next‐generation sequencing (NGS)‐based chimerism assay (CASAL) in haematopoietic stem cell transplantation (HSCT). Compared to conventional short tandem repeat (STR) methods, CASAL showed significantly higher marker informativeness, detecting mixed chimerism (MC) below 5% recipient DNA with a median of ...
Jin Ju Kim, Soon Sung Kwon, Yu Jeong Choi, Yehyun Kang, Yu Jin Park, Saeam Shin, Seung‐Tae Lee, Jong Rak Choi   +7 more
wiley   +1 more source

A prior status of graft‐versus‐host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation

British Journal of Haematology, EarlyView.
Summary Optimizing the effectiveness of donor lymphocyte infusion (DLI) for relapse after allogeneic stem cell transplantation (alloHSCT) has been challenging. We investigated whether the benefits of achieving full donor chimerism (FDC) and developing graft‐versus‐host disease (GVHD) after DLI are affected by a history of GVHD before DLI.
Claudia Mae Velasco, Yoshitaka Inoue, Joseph Cioccio, Kevin Rakszawski, Natthapol Songdej, Myles Nickolich, Hong Zheng, Seema Naik, Christopher Ehmann, Joseph Mierski, Brooke Silar, Caitlin Vajdic, Robert Greiner, Valerie Brown, Shin Mineishi, Hiroko Shike, Kentaro Minagawa   +16 more
wiley   +1 more source

Modern Approach to Nodal T-Cell Lymphomas. [PDF]

Adv Anat Pathol
Ondrejka SL, de Leval L, de Leval L.
europepmc   +1 more source

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski   +11 more
wiley   +1 more source

Effective venetoclax treatment for indolent T-cell lymphoma of the gastrointestinal tract: a case report and literature review. [PDF]

Front Immunol
Jian JM, Hao HY, Yuan CL, Zhang SQ, Huang ZF, Du J.   +5 more
europepmc   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

British Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu, Xipeng Yue, Xinrong Zhan, Xiaojuan Liu, Hongxia Ma, Fuli Qin, Lijuan Duan, Hongmian Zhao, Yan Zhang, Shiqiang He, Huifang Zhao, Chunlei Zhang, Xiangke Xin, Wenli Zhang, Yongping Song, Bingcheng Liu, Weiming Li, Yanli Zhang   +17 more
wiley   +1 more source

Successful Re-administration and Extended Dosing of Brentuximab Vedotin Monotherapy for Relapsed Anaplastic Large Cell Lymphoma in a Vulnerable Patient. [PDF]

Cureus
Minemura T, Kikuchi S, Fujihira T, Nabe Y, Horaguchi R, Kamihara Y, Wada A, Ono K, Katou T, Sato T.   +9 more
europepmc   +1 more source